The spectrum of structural damage in the brain associated with HIV is now m
ore fully understood. Such changes include inflammatory disorders (such as
HIV encephalitis, leukoencephalopathy, and diffuse poliodystrophy), dendrit
ic and synaptic damage, and neuronal loss. However, the relationship betwee
n neuronal damage and loss and clinical variables is still not clear. In my
laboratory my research group has been addressing three separate areas, whi
ch will be the subject of this presentation. (1) The relationship of neuron
al damage and loss to various clinical features such as cognitive symptoms,
and risk group. (2) The cellular site of production of neurotoxic factors
in the HIV-infected brain. (3) Assessing potential neuroprotective strategi
es using appropriate in-vitro models.